Combination of @entity2449 and XXXX synergistically induces cell cycle arrest and apoptosis in @entity1358 .

@entity1 @entity3262 @entity1092 @entity1358 @entity98 @entity2449
OBJECTIVE: To investigate the antitumor activity of @entity2449 combined with @entity1092 ( @entity3262 ) on @entity1358 ( @entity1358 ) cell lines. METHODS: The effects of @entity2449 combined with @entity3262 on the viability of @entity1 and caki-2 cell lines were evaluated by @entity98 assay. The inhibitory effect of combination of the two drugs was analyzed by the Chou and Talalay method. Flow cytometry was employed to analyze cell cycle and cell apoptosis. RESULTS: @entity98 assay showed that both @entity2449 and @entity3262 decreased @entity1 and Caki-2 cells viability in a dose-dependent and time-dependent manner. In @entity1 cells, @entity2449 combined with @entity3262 had a synergistic inhibitory effect (CI < 1) when the inhibition effect was >=  0.3. In Caki-2 cells, @entity2449 combined with @entity3262 had a synergistic inhibitory effect (CI < 1) when the inhibition effect was >=  0.4. @entity2449 and @entity3262 combination elicited significant apoptosis compared to drug used alone (P < 0.05). Furthermore, @entity2449 and @entity3262 acted synergistically to arrest @entity1 and Caki-2 cells in G0/G1 phase. CONCLUSION: We highlighted for the first time that @entity2449 combined with @entity3262 could significantly increase anti-ccRCC effect through synergetic effect; its possible mechanisms were inducing apoptosis and adjusting cell cycle.
